跳至主要内容
临床试验/NCT02641938
NCT02641938已完成4 期

Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: a Double-blind Randomized Clinical Trial

Gangnam Severance Hospital1 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2015年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
38
试验地点
1
主要终点
Change of Creatinine clearance from baseline

研究概览

简要总结

To investigate the renal protective effect of dexmedetomidine in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy

详细描述

A cytoreductive surgery and hyperthermic intraperitoneal chemotherapy may lead to the renal hypoperfusion, systemic inflammatory response, and oxidative stress. Dexmedetomidine has been known to protect the kidney against inflammation and oxidative stress in diverse clinical settings. It may also enhance a renal perfusion by inhibition of renal sympathoexcitation. We hypothesized administration of dexmedetomidine might protect the kidney in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of malignant tumor with peritoneal metastasis
  • Scheduled for elective cytoreduction and hyperthermic intraperitoneal chemotherapy

排除标准

  • Preoperative chronic kidney disease stage ≥4 defined by KDOQI ( eGFR < 30 mL/min/1.73m2)
  • Congestive heart failure
  • Atrioventricular block > 1st degree
  • Bradycardia < 45 beat per minute
  • History of myocardial infarction within 3 months
  • Pregnancy

研究组 & 干预措施

Dexmedetomidine

Experimental

1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery

干预措施: Dexmedetomidine (Drug)

Normal Saline

Placebo Comparator

IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery

干预措施: Normal Saline (Drug)

结局指标

主要结局

Change of Creatinine clearance from baseline

时间窗: Postoperative day 1,2,3,4,5,6,7

Assessment of the creatinine clearance which reflects kidney function during postoperative 7 days

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ji-young Kim

Associate Professor, Yonsei University Medical College

Gangnam Severance Hospital

研究点 (1)

Loading locations...

相似试验